Johnson & Johnson (JNJ) has struck a deal with the Trump administration that boils down to a straightforward trade: lower drug prices in exchange for dodging tariffs. The agreement, announced Thursday, keeps the specifics close to the vest—no word yet on which medicines are getting cheaper or by exactly how much.
What we do know is that Johnson & Johnson committed to offering substantially reduced prices through the TrumpRx.gov website and extending Medicaid access at rates that match what other developed countries pay. It's part of a broader push by the administration to bring American drug prices down from their notoriously high perch.
The healthcare giant also reaffirmed its manufacturing expansion plans, announcing two new production facilities in North Carolina and Pennsylvania. These plants are part of a $55 billion U.S. investment strategy the company unveiled last year, with additional investment announcements expected before year-end.
The Drug Pricing Truce Shows Some Cracks
This agreement follows a similar pattern established in December when nine other major pharmaceutical companies made comparable commitments to the Trump administration. Those deals aimed to align U.S. drug prices more closely with international rates, targeting both Medicaid and cash-paying customers.
But here's the tension: despite these high-profile pricing agreements, the pharmaceutical industry is reportedly planning to raise prices on at least 350 branded medicines in 2026. We're talking about vaccines for COVID-19, RSV, and shingles, plus major cancer treatments. So while one hand giveth, the other apparently still taketh away.
Johnson & Johnson has had its share of pricing disputes with federal regulators. Last July, a federal court rejected the company's attempt to restructure its participation in the 340B Drug Pricing Program following a clash with the U.S. Department of Health and Human Services. That program requires pharmaceutical manufacturers in Medicaid and Medicare Part B to sell outpatient drugs at discounted rates to healthcare providers serving low-income and rural communities.
Price Action: Johnson & Johnson stock has climbed 44.83% over the past year. Shares edged 0.28% higher on Tuesday to close at $660.62.
